February 28, 2017 / 1:15 PM / 5 months ago

BRIEF-Kite Pharma posts Q4 adj. loss per share $1.31

1 Min Read

Feb 28 (Reuters) - Kite Pharma Inc

* Kite reports fourth quarter and full year 2016 financial results

* Q4 non-GAAP loss per share $1.31 excluding items

* Says expects to have sufficient cash resources to fund its current operations through first half of 2018

* Q4 loss per share $1.70

* Q4 earnings per share view $-1.75 -- Thomson Reuters I/B/E/S

* Sees FY 2017 revenue $40 million to $50 million

* Q4 revenue $4.9 million versus I/B/E/S view $5.6 million

* Sees full year 2017 GAAP operating expenses to be between $490 million and $515 million Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below